D. Boral Capital CytoSorbens says (CTSO) posted a strong performance in the fourth quarter, with product revenue growing between 22% and 25% year over year. The company also showed a significant rebound in gross profit margin to around 70%, underscoring operational resilience and efficiency improvements, the analyst told investors in a research note. Dr. believes. Boral said the results highlight CytoSorbents’ strong execution and growing demand for CytoSorb, its flagship product. The company maintains a $10 buy rating on the stock Price target
First published on The fly – The ultimate source for breaking financial news that moves the market in real time. Try now >>
See Hot Stocks for Insiders on TipRanks >>
Read more about CTSO: